Spectrum Pharmaceuticals, Inc.  

(Public, NASDAQ:SPPI)   Watch this stock  
Find more results for SPPI
6.14
-0.13 (-2.07%)
Jun 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.11 - 6.37
52 week 5.45 - 9.27
Open 6.30
Vol / Avg. 841,966.00/1.19M
Mkt cap 420.06M
P/E     -
Div/yield     -
EPS -0.67
Shares 67.00M
Beta 1.79
Inst. own 79%
Aug 5, 2015
Q2 2015 Spectrum Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Jun 29, 2015
Spectrum Pharmaceuticals Inc Annual Shareholders Meeting - 1:30PM EDT - Add to calendar
Jun 3, 2015
Spectrum Pharmaceuticals Inc at Jefferies Global Healthcare Conference - 10:00AM EDT - Add to calendar
May 7, 2015
Q1 2015 Spectrum Pharmaceuticals Inc Earnings Call - Webcast
May 7, 2015
Q1 2015 Spectrum Pharmaceuticals Inc Earnings Release
Mar 24, 2015
Spectrum Pharmaceuticals Inc at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 13, 2015
Q4 2014 Spectrum Pharmaceuticals Inc Earnings Call & Analyst Day
Mar 13, 2015
Q4 2014 Spectrum Pharmaceuticals Inc Earnings Release
Mar 9, 2015
Spectrum Pharmaceuticals Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -66.19% -24.47%
Operating margin -56.09% -16.90%
EBITD margin - -3.31%
Return on average assets -21.39% -9.24%
Return on average equity -42.31% -17.06%
Employees 241 -
CDP Score - -

Address

11500 S Eastern Ave Ste 240
HENDERSON, NV 89052-5576
United States - Map
+1-702-8356300 (Phone)
+1-702-2607405 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology Company. The Company is engaged in commercial and drug development operations with a focus on hematology and oncology. The Company is engaged in acquiring, developing and commercializing the pipeline of late-stage clinical and commercial products. Spectrum’s products include: Fusilev, which is an injection for patients in the United States with advanced metastatic colorectal cancer and to counteract certain side effects of methotrexate therapy; Zevalin injection for patients in the United States and various international markets with follicular Non-Hodgkin’s Lymphoma; Folotyn injection for patients in the United States with relapsed or refractory peripheral t-cell lymphoma, and Marqibo injection for patients in the United States with relapsed Philadelphia chromosome negative acute lymphoblastic leukemia.

Officers and directors

Rajesh C. Shrotriya M.D. Chairman of the Board, Chief Executive Officer
Age: 71
Bio & Compensation  - Reuters
Joseph W. Turgeon President, Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
Kurt A. Gustafson Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Lee F. Allen M.D. Ph.D. Senior Vice President, Chief Medical Officer
Age: 63
Bio & Compensation  - Reuters
Gilles R. Gagnon Director
Age: 61
Bio & Compensation  - Reuters
Raymond W. Cohen Independent Director
Age: 56
Bio & Compensation  - Reuters
Stuart M. Krassner Independent Director
Age: 79
Bio & Compensation  - Reuters
Luigi Lenaz M.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Anthony E. Maida III, Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters